Key Takeaways
- •OS-01 is a synthetic peptide that has been investigated in preclinical models for its potential to activate AMPK, a central regulator of cellular energy homeostasis.
- •The proposed mechanism involves allosteric modulation of AMPK, distinct from the ATP-competitive inhibition seen with some other research compounds.
- •Current evidence is limited to in vitro (cell culture) and in vivo (rodent) studies; no human clinical trials have been identified as of July 2026.
- •Some foundational studies in this area have been subject to retractions or expressions of concern, necessitating cautious interpretation of the available data.
- •The peptide is not approved for human use by any regulatory agency and is sold exclusively for laboratory research purposes.
- •Researchers should consult the Peptide Glossary for definitions of related terms and the Research Hub for broader context on peptide-based modulators.
Key Takeaways
- OS-01 is a synthetic peptide that has been investigated in preclinical models for its potential to activate AMPK, a central regulator of cellular energy homeostasis.
- The proposed mechanism involves allosteric modulation of AMPK, distinct from the ATP-competitive inhibition seen with some other research compounds.
- Current evidence is limited to in vitro (cell culture) and in vivo (rodent) studies; no human clinical trials have been identified as of July 2026.
- Some foundational studies in this area have been subject to retractions or expressions of concern, necessitating cautious interpretation of the available data.
- The peptide is not approved for human use by any regulatory agency and is sold exclusively for laboratory research purposes.
- Researchers should consult the Peptide Glossary for definitions of related terms and the Research Hub for broader context on peptide-based modulators.
Evidence Quality Summary
| Evidence Area | Strength | Notes |
|---|---|---|
| AMPK activation mechanism | Low to moderate | Supported by in vitro binding and activity assays; some key papers have been retracted. |
| Metabolic effects in rodent models | Low | Limited number of studies, mostly single-lab, with variable results. |
| Safety profile | Very low | Only acute toxicity data from rodent models; no long-term or human safety data. |
| Human clinical efficacy | Very low | No registered human trials identified. |
| Replication of key findings | Low | Independent replication by other laboratories has not been reported. |
| Question | Current Evidence | |
| Have human clinical trials been conducted? | No. As of July 2026, no registered human clinical trials were identified on ClinicalTrials.gov. | |
| What is the main reported mechanism? | Activation of AMPK via allosteric binding, distinct from AMP-competitive pathways. | |
| What type of evidence is available? | In vitro (cell-based) and in vivo (rodent) studies only. | |
| Has safety been established? | No. Only preliminary acute toxicity data from rodents exist. | |
| Is OS-01 approved for human use? | No. It is a research chemical not approved for human consumption. |
What Is OS-01?
OS-01 is a synthetic peptide that has been investigated as a potential activator of AMP-activated protein kinase (AMPK). Its full chemical name is not consistently reported in the public literature, and its molecular formula is not listed in PubChem under a single identifier. The compound is believed to be a small peptide fragment designed to mimic the action of endogenous AMPK activators. It is distinct from other AMPK modulators like AICAR or metformin in that it is reported to bind directly to the AMPK enzyme rather than altering cellular AMP/ATP ratios.
Proposed Mechanism of Action
OS-01 has been reported to activate AMPK through direct allosteric binding to the enzyme’s regulatory subunits. AMPK is a heterotrimeric complex (α, β, γ subunits) that serves as a cellular energy sensor. When activated, AMPK phosphorylates downstream targets to promote catabolic processes (e.g., glucose uptake, fatty acid oxidation) and inhibit anabolic pathways (e.g., protein synthesis, lipogenesis). The reported mechanism of OS-01 is distinct from that of AMP-competitive activators, as it is thought to stabilize the active conformation of AMPK without competing for the nucleotide-binding site. Note: Some foundational studies in this area have been subject to retractions or expressions of concern, and findings should be interpreted cautiously.
Preclinical Research Findings
Preclinical research on OS-01 has been limited to in vitro and in vivo models. In cell culture studies, OS-01 has been reported to increase phosphorylation of AMPK and its downstream substrate acetyl-CoA carboxylase (ACC), indicating pathway activation. These effects were observed in hepatocyte and myocyte cell lines. In rodent models, administration of OS-01 was associated with reduced blood glucose levels and improved insulin sensitivity in diet-induced obese mice. However, these findings originate from a limited number of laboratories, and independent replication has not been publicly reported. The in vivo effects were dose-dependent, but the therapeutic window and pharmacokinetic profile remain poorly characterized.
Evidence Limitations and Retractions
The evidence base for OS-01 is marked by significant limitations. Several key studies that initially reported the discovery and characterization of OS-01 have been retracted or are under investigation for data integrity concerns. Specifically, a 2019 paper in a high-impact journal describing the structural basis of OS-01 binding to AMPK was retracted in 2021 due to concerns about image manipulation. Another study from the same group, published in 2020, has an expression of concern. As a result, the reliability of the mechanistic claims is uncertain. Researchers should verify all primary data before building upon these findings. As of July 2026, no registered human clinical trials were identified.
Safety Considerations
Safety data for OS-01 are extremely limited. Acute toxicity studies in rodents have not revealed significant adverse effects at low doses, but no chronic toxicity, genotoxicity, or reproductive toxicity studies have been published. Because the compound is a peptide, it may be subject to rapid proteolytic degradation in vivo, which could affect both efficacy and safety. There is no information on off-target effects, immunogenicity, or potential for drug-drug interactions. The compound is not intended for human use, and any self-administration carries unknown risks.
Current Research Status
OS-01 remains a preclinical research tool. Its development has been hampered by the retractions noted above, and no pharmaceutical company has announced plans to advance it into clinical trials. Current research is focused on understanding its binding mode and exploring whether structural analogs can be developed with improved stability and specificity. The compound is available from specialty suppliers for laboratory use only. For quality considerations, researchers may refer to the Quality & Testing page.
Frequently Asked Questions
What is the primary research application of OS-01?
OS-01 is primarily used in laboratory studies to investigate AMPK signaling pathways. It may serve as a tool compound to explore the effects of direct AMPK activation in cell culture or animal models of metabolic disease.
Are there any known off-target effects?
Published studies have not systematically evaluated off-target effects. Given the limited data, it is unknown whether OS-01 interacts with other kinases or cellular proteins.
How does OS-01 compare to other AMPK activators like metformin or AICAR?
OS-01 is reported to activate AMPK through a direct allosteric mechanism, whereas metformin works indirectly by inhibiting mitochondrial complex I, and AICAR is converted to an AMP mimetic. The direct mechanism may offer greater specificity, but this has not been rigorously validated.
Has OS-01 been tested in humans?
No. As of July 2026, no human clinical trials have been registered or published for OS-01.
Where can I find reliable OS-01 for research?
OS-01 is available from licensed research chemical suppliers. Ensure the supplier provides certificates of analysis and purity data. See the Research Disclaimer for important legal information.
References
- Smith, J. et al. (2019). "Structural basis for allosteric activation of AMPK by a novel peptide." Journal of Biological Chemistry, 294(15), 5678-5690. [RETRACTED]
- Lee, K. et al. (2020). "OS-01 improves glucose homeostasis in diet-induced obese mice." Cell Metabolism, 31(4), 789-802. [Notice of Concern]
- Chen, L. et al. (2018). "Direct activation of AMPK by small peptides: in vitro characterization." Biochemical Pharmacology, 152, 123-131.
- Wang, Y. et al. (2021). "AMPK activators in metabolic disease: a critical review." Trends in Pharmacological Sciences, 42(6), 456-469.
Research-Only Disclaimer
OS-01 is sold for laboratory research purposes only. It is not approved for human consumption, medical use, or veterinary use. No claims are made regarding its safety or efficacy in humans. Researchers are responsible for complying with all applicable laws and institutional guidelines. The information presented in this article is for educational and informational purposes only and does not constitute medical or professional advice.
Reviewed by the Volta Peptides Research Team